Safety of Recombinant Adeno-Associated Virus Type 2–RPE65 Vector Delivered by Ocular Subretinal Injection
Samuel G. Jacobson(Penn Presbyterian Medical Center), William W. Hauswirth(University of Florida), Tomás S. Alemán(Children's Hospital of Philadelphia), Thomas J. Conlon(Adelson Foundation), Geoffrey K. Aguirre(University of Pennsylvania), Caroline J. Zeiss(Yale University), Artur V. Cideciyan(University of Pennsylvania), András M. Komáromy(University of Pennsylvania), Jean Bennett(Penn Presbyterian Medical Center), Alejandro J. Román(Penn Presbyterian Medical Center), Elizabeth A. M. Windsor(Penn Presbyterian Medical Center), Alexander Sumaroka(Penn Presbyterian Medical Center), Susan E. Pearce-Kelling(Cornell University), Gregory M. Acland(Cornell University), Albert M. Maguire(Children's Hospital of Philadelphia), Sharon Schwartz(Penn Presbyterian Medical Center), Shalesh Kaushal(University of Florida), Sanford L. Boye(University of Florida), Vincent A. Chiodo(University of Florida), Terence R. Flotte(University of Massachusetts Chan Medical School)
Cited by 223
Related Papers
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
|New England Journal of Medicine|2008|2.1k
Treatment of Leber Congenital Amaurosis Due to <i>RPE65</i> Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial
|Human Gene Therapy|2008|950
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
|The Lancet|2009|864